Decrease in BMP2-induced Smad1/5/8 phosphorylation due to Panx3 siRNA. by Tsutomu Iwamoto (715969)

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…Data are the mean ± SD of three independent SYBR Green based qRT-PCR experiments. …”

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs. by Xinhai Ye (6857771)

“…<p>(A) Antagomir-34 (with two different quantities) and ds<i>NlInR2</i> (0.84 ng) were injected into the third instar SW strain nymphs, showed that injection of antagomir-34 decreased the ratio of SW type BPH (Chi-square test, 40ng: χ² = 5.8, df = 1, <i>p</i> = 0.003; 60ng: χ² = 7.9, df = 1, <i>p</i> = 0.042). …”

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: